Ability of Nafamostat Mesilate to Prolong Filter Patency during Continuous Renal Replacement Therapy in Patients at High Risk of Bleeding: A Randomized Controlled Study-Reference-Cited by-同舟云学术

Ability of Nafamostat Mesilate to Prolong Filter Patency during Continuous Renal Replacement Therapy in Patients at High Risk of Bleeding: A Randomized Controlled Study

Published:2014-10-10 Issue:10 Volume:9 Page:e108737
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Lee Yong Kyu,Lee Hae Won,Choi Kyu Hun,Kim Beom Seok

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference31 articles.

1. Extracorporeal treatment of acute renal failure in the intensive care unit: a critical view;M Schetz;Intensive care medicine,1989

2. Anticoagulation for continuous renal replacement therapy;AJ Tolwani;Seminars in dialysis,2009

3. Regional citrate anticoagulation for continuous renal replacement therapy: the better alternative?;A Tolwani;American journal of kidney diseases: the official journal of the National Kidney Foundation,2012

4. Heparin use in continuous renal replacement procedures: the struggle between filter coagulation and patient hemorrhage;J van de Wetering;Journal of the American Society of Nephrology: JASN,1996

5. Filter run time in CVVH: pre- versus post-dilution and nadroparin versus regional heparin-protamine anticoagulation;PH van der Voort;Blood purification,2005

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How to safeguard the continuous renal replacement therapy circuit: a narrative review;Frontiers in Medicine;2024-08-21

2. Low-Dose Continuous Kidney Replacement Therapy and Mortality in Critically Ill Patients With Acute Kidney Injury: A Retrospective Cohort Study;American Journal of Kidney Diseases;2024-08

3. The role of nafamostat mesylate anticoagulation in continuous kidney replacement therapy for critically ill patients with bleeding tendencies: a retrospective study on patient outcomes and safety;Kidney Research and Clinical Practice;2024-07-31

4. Dose of nafamostat mesylate during continuous kidney replacement therapy in critically ill patients: a two-centre observational study;BMC Nephrology;2024-02-26

5. Nafamostat mesylate versus regional citrate anticoagulation for continuous renal replacement therapy in patients at high risk of bleeding: a retrospective single-center study;European Journal of Medical Research;2024-01-20